ANDA 90618, held by Glenmark Pharms. Nizatidine.
As of Nov 15, 2026, ANDA 90618 (Nizatidine), held by Glenmark Pharms, was first approved by FDA on Jul 15, 2011, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 2011 | Original application | Approved | None posted |
| Nizatidine150MG · capsule;oral | Nizatidine | Discontinued |
| Nizatidine300MG · capsule;oral | Nizatidine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
